CNSP News and Press, CNS Pharmaceuticals Inc. From 12/05/22

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor ...

CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event PR Newswire Live moderated video webcast event intended to provide the investment community direct access to ask their questions to John Climaco , Chief Executive Officer on Tuesday, December ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stoc...

CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price PR Newswire HOUSTON , Nov. 30, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company s...

Brain cancer is one of the most debilitating conditions on the planet. Affecting an estimated 700,000 Americans, the condition has no cure and is often associated with poor negative outcomes, especially when diagnosed late. The main treatment options for brain cancer are surgery, chemother...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the spl...

CNS Pharmaceuticals Announces Reverse Stock Split PR Newswire HOUSTON , Nov. 28, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatment...

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical developm...

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and o...

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubic...